Investor Presentaiton
For personal use only
Recent milestones and near-term catalysts
TELIX
PHARMACEUTICALS
Recently completed milestones
.
Illuccix regulatory approvals granted in US
and Australia
HCPCS1 reimbursement submitted for Illuccix
in the US
ProstACT patient recruitment commenced
Distributors finalised for major EU markets
(subject to regulatory approval)
FDA Investigational New Drug (IND) granted
for STARLITE 1 & 2 studies for renal cancer
therapy
Upcoming milestones: Q1 2022
·
•
Illuccix commercial launch US and AU
US reimbursement for Illuccix:
•
Pass-through code submission (March 2022)
HCPCS code for US reimbursement
expected 1 April 2022
Illuccix EU marketing authorisation decision
ZIRCON Phase III study enrolment completed
IPAX-2 Phase II study launched (glioblastoma)
STARLITE Phase II kidney cancer therapy
studies progressed
1. Healthcare Common Procedure Coding System
Telix Pharmaceuticals Limited (ASX: TLX)
80View entire presentation